title: Erythropoietin does not affect nitric oxide system in rats with chronic renal failure.
abstract: We investigated to see whether an altered role of nitric oxide (NO) system is involved in erythropoietin (EPO)-induced hypertension in chronic renal failure (CRF). Male Sprague-Dawley rats were five-sixths nephrectomized to induce CRF. Six weeks after the operation, EPO or vehicle was injected for another 6 weeks. Plasma and urine nitrite/nitrate (NOx) levels were determined. Expression of NO synthase (NOS) proteins in the aortae and kidneys were also determined. In addition, the isometric tension of isolated aorta in response to acetylcholine and nitroprusside was examined. Blood pressure progressively rose in CRF groups, the degree of which was augmented by EPO treatment. Plasma NOx levels did not differ among the groups, while urine NOx levels were lower in CRF groups. Endothelial NOS expression was lower in the kidney and aorta in CRF rats, which was not further affected by EPO-treatment. The inducible NOS expression in the kidney and aorta was not different among the groups. Acetylcholine and sodium nitroprusside caused dose-dependent relaxations of aortic rings, the degree of which was not altered by EPO-treatment. Taken together, EPO-treatment aggravates hypertension in CRF, but altered role of NO system may not be involved.
authors.affiliation: Department of Internal Medicine, Chonnam National University Medical School, Kwangju, Korea.
authors.forename: S W
authors.initials: SW
authors.lastname: Kim
authors.forename: J
authors.initials: J
authors.lastname: Lee
authors.forename: D G
authors.initials: DG
authors.lastname: Kang
authors.forename: K
authors.initials: K
authors.lastname: Jung
authors.forename: N H
authors.initials: NH
authors.lastname: Kim
authors.forename: S P
authors.initials: SP
authors.lastname: Suh
authors.forename: K C
authors.initials: KC
authors.lastname: Choi
authors.forename: Y J
authors.initials: YJ
authors.lastname: Kang
mesh_terms: D000109:Acetylcholine / Q000494:pharmacology; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D000818:Animals; D001013:Aorta, Thoracic / Q000502:physiology; D001835:Body Weight; D004921:Erythropoietin / Q000494:pharmacology*; D006977:Hypertension, Renal / Q000188:drug therapy / Q000378:metabolism; D007537:Isometric Contraction / Q000187:drug effects; D007668:Kidney / Q000201:enzymology; D007676:Kidney Failure, Chronic / Q000150:complications / Q000378:metabolism*; D008297:Male; D009566:Nitrates / Q000097:blood / Q000652:urine; D009569:Nitric Oxide / Q000378:metabolism*; D019001:Nitric Oxide Synthase / Q000378:metabolism; D009573:Nitrites / Q000097:blood / Q000652:urine; D009599:Nitroprusside / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D014661:Vasoconstriction / Q000187:drug effects; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D009566:Nitrates; D009573:Nitrites; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D004921:Erythropoietin; D009599:Nitroprusside; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase; D000109:Acetylcholine